Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/48769
Title: Complementing the net benefit approach: A new framework for Bayesian cost-effectiveness analysis
Authors: Hernández, Miguel Angel Negrín 
Vázquez-Polo, Francisco José 
Gonzélez-Torre, Francisco Javier Girón
Bas, Elías Moreno
Keywords: Effectiveness Acceptability Curves
Effectiveness Ratios
Clinical-Trials
Uncertainty
Issue Date: 2009
Publisher: 0266-4623
Journal: International Journal of Technology Assessment in Health Care 
Abstract: Objectives: The aim of cost-effectiveness analysis is to maximize health benefits from a given budget, taking a societal perspective. Consequently, the comparison of alternative treatments or technologies is solely based. on their expected effectiveness and cost. However, the expectation, or mean, poses important limitations as it might be a poor summary of the underlying distribution, for instance when the effectiveness is a categorical variable, or when the distributions of either effectiveness or cost present a high degree of asymmetry. Clinical variables often present these characteristics.Methods: In this study, we present a framework for cost-effectiveness analysis based on the whole posterior distribution of effectiveness and cost.Results: An application with real data is included to illustrate the analysis. Decision-making measures such as the incremental cost-effectiveness ratio, incremental net-benefit, and cost-effectiveness acceptability curves, can also be defined under the new framework.Conclusions: This framework overcomes limitations of the mean and offers complementary information for the decision maker.
URI: http://hdl.handle.net/10553/48769
ISSN: 0266-4623
DOI: 10.1017/S0266462309990444
Source: International Journal of Technology Assessment in Health Care[ISSN 0266-4623],v. 25, p. 537-545
Appears in Collections:Artículos
Show full item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.